💊 Torrent Pharma Posts ₹1,911 Cr Profit in FY25 — But Is the Stock Already Too Expensive?

🧠 At a glance:

  • FY25 PAT: ₹1,911 crore (+15% YoY)
  • Revenue: ₹11,516 crore (+7%)
  • Q4 PAT: ₹498 crore (+11%)
  • Dividend: ₹6/share final, ₹26/share interim = ₹32/share total

👨‍⚕️ About the Company

Torrent Pharma is the Amitabh Bachchan of Indian pharma – veteran,

versatile, and always in the race. It operates in key therapies like cardiology, diabetology, gastro, CNS, and women’s health with presence in India, US, Germany, Brazil, and other markets.

🧑‍💼 Key Managerial Personnel (KMP)

  • Chairman: Samir Mehta
To Read Full 16 Point ArticleBecome a member
Become a member
To Read Full 16 Point ArticleBecome a member

Leave a Comment

error: Content is protected !!